Abzena’s Dr. Jeffrey C. Mocny and Cellares’ Anna McMahon discuss how biopharmaceutical risk-based standards accelerate innovation and speed-to-market by leveraging data for better patient outcomes and safety.
Anna McMahon
Advertisement
Anna McMahon is director of Regulatory Affairs at Cellares.
Articles by Anna McMahon
Advertisement
Latest Updated Articles
Advertisement
Advertisement